The NASH project is licensed to LG Chem and is run in a collaboration in which LG Chem is responsible for all development costs.
NASH (Non-Alcoholic Steatohepatitis) is a serious liver disease which currently has no existing treatments. In our NASH project, we work with a new mechanism of action and a new target protein that has been shown to be involved in fat storage in liver and other tissues, inflammatory response and fibrosis in NASH. This allows us to develop treatments that may slow down the development of both early and late stages of NAFLD (Non-Alcoholic Fatty Liver Disease)/NASH, either as monotherapy or in combination with other NASH preparations.
